Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-β: A longitudinal study in multiple sclerosis patients

A. J. Sánchez López, L. Román-Vega, E. Ramil Tojeiro, Andrea Giuffrida, A. García-Merino

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Summary: Evidence suggests the involvement of the cannabinoid system in the pathogenesis of multiple sclerosis (MS). We studied cannabinoid receptor (CB)1 and CB2 receptor gene expression in B, natural killer (NK) and T cells from MS patients before and after 1year of interferon beta therapy, and compared these levels to those of healthy controls. We also measured the production of the endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) and the gene expression of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) in these cells. Prior to interferon therapy, MS patients showed significantly elevated CB<inf>2</inf> expression in B cells, but not in T or NK cells. These levels decreased gradually within 6 months to 1year of interferon treatment. CB<inf>1</inf> expression was elevated in all cell subsets, but only reached statistical significance in T cells; all levels decreased progressively over time. Before treatment, AEA but not 2-AG levels were significantly elevated in the three cell populations; after 1year of treatment, all values decreased to control levels. The expression of FAAH was unchanged. The different expression of cannabinoid receptor genes and the increased level of AEA in lymphocytes point to a possible role of the cannabinoid system in MS immune response and its modulation by interferon.

Original languageEnglish (US)
Pages (from-to)119-127
Number of pages9
JournalClinical and Experimental Immunology
Volume179
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Cannabinoid Receptors
Endocannabinoids
Lymphocyte Subsets
Interferons
Multiple Sclerosis
Longitudinal Studies
Gene Expression
Cannabinoid Receptor CB2
Natural Killer T-Cells
Cannabinoids
Therapeutics
Interferon-beta
B-Lymphocytes
Lymphocytes
T-Lymphocytes
Enzymes
Population
Genes

Keywords

  • Cannabinoid receptors
  • Endocannabinoids
  • Interferon beta
  • Multiple sclerosis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-β : A longitudinal study in multiple sclerosis patients. / Sánchez López, A. J.; Román-Vega, L.; Ramil Tojeiro, E.; Giuffrida, Andrea; García-Merino, A.

In: Clinical and Experimental Immunology, Vol. 179, No. 1, 01.01.2015, p. 119-127.

Research output: Contribution to journalArticle

@article{611e2a5010af470d901da90499c90b9b,
title = "Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-β: A longitudinal study in multiple sclerosis patients",
abstract = "Summary: Evidence suggests the involvement of the cannabinoid system in the pathogenesis of multiple sclerosis (MS). We studied cannabinoid receptor (CB)1 and CB2 receptor gene expression in B, natural killer (NK) and T cells from MS patients before and after 1year of interferon beta therapy, and compared these levels to those of healthy controls. We also measured the production of the endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) and the gene expression of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) in these cells. Prior to interferon therapy, MS patients showed significantly elevated CB2 expression in B cells, but not in T or NK cells. These levels decreased gradually within 6 months to 1year of interferon treatment. CB1 expression was elevated in all cell subsets, but only reached statistical significance in T cells; all levels decreased progressively over time. Before treatment, AEA but not 2-AG levels were significantly elevated in the three cell populations; after 1year of treatment, all values decreased to control levels. The expression of FAAH was unchanged. The different expression of cannabinoid receptor genes and the increased level of AEA in lymphocytes point to a possible role of the cannabinoid system in MS immune response and its modulation by interferon.",
keywords = "Cannabinoid receptors, Endocannabinoids, Interferon beta, Multiple sclerosis",
author = "{S{\'a}nchez L{\'o}pez}, {A. J.} and L. Rom{\'a}n-Vega and {Ramil Tojeiro}, E. and Andrea Giuffrida and A. Garc{\'i}a-Merino",
year = "2015",
month = "1",
day = "1",
doi = "10.1111/cei.12443",
language = "English (US)",
volume = "179",
pages = "119--127",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-β

T2 - A longitudinal study in multiple sclerosis patients

AU - Sánchez López, A. J.

AU - Román-Vega, L.

AU - Ramil Tojeiro, E.

AU - Giuffrida, Andrea

AU - García-Merino, A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Summary: Evidence suggests the involvement of the cannabinoid system in the pathogenesis of multiple sclerosis (MS). We studied cannabinoid receptor (CB)1 and CB2 receptor gene expression in B, natural killer (NK) and T cells from MS patients before and after 1year of interferon beta therapy, and compared these levels to those of healthy controls. We also measured the production of the endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) and the gene expression of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) in these cells. Prior to interferon therapy, MS patients showed significantly elevated CB2 expression in B cells, but not in T or NK cells. These levels decreased gradually within 6 months to 1year of interferon treatment. CB1 expression was elevated in all cell subsets, but only reached statistical significance in T cells; all levels decreased progressively over time. Before treatment, AEA but not 2-AG levels were significantly elevated in the three cell populations; after 1year of treatment, all values decreased to control levels. The expression of FAAH was unchanged. The different expression of cannabinoid receptor genes and the increased level of AEA in lymphocytes point to a possible role of the cannabinoid system in MS immune response and its modulation by interferon.

AB - Summary: Evidence suggests the involvement of the cannabinoid system in the pathogenesis of multiple sclerosis (MS). We studied cannabinoid receptor (CB)1 and CB2 receptor gene expression in B, natural killer (NK) and T cells from MS patients before and after 1year of interferon beta therapy, and compared these levels to those of healthy controls. We also measured the production of the endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) and the gene expression of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) in these cells. Prior to interferon therapy, MS patients showed significantly elevated CB2 expression in B cells, but not in T or NK cells. These levels decreased gradually within 6 months to 1year of interferon treatment. CB1 expression was elevated in all cell subsets, but only reached statistical significance in T cells; all levels decreased progressively over time. Before treatment, AEA but not 2-AG levels were significantly elevated in the three cell populations; after 1year of treatment, all values decreased to control levels. The expression of FAAH was unchanged. The different expression of cannabinoid receptor genes and the increased level of AEA in lymphocytes point to a possible role of the cannabinoid system in MS immune response and its modulation by interferon.

KW - Cannabinoid receptors

KW - Endocannabinoids

KW - Interferon beta

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84927694130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927694130&partnerID=8YFLogxK

U2 - 10.1111/cei.12443

DO - 10.1111/cei.12443

M3 - Article

C2 - 25169051

AN - SCOPUS:84927694130

VL - 179

SP - 119

EP - 127

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 1

ER -